Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program

Michael A Pfaller; Linda Boyken; Richard J Hollis; Jennifer Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema

doi:10.1016/j.diagmicrobio.2009.05.007

Back

Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program

Journal article

Peer reviewed

Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program

Michael A Pfaller, Linda Boyken, Richard J Hollis, Jennifer Kroeger, Shawn A Messer, Shailesh Tendolkar and Daniel J Diekema

Diagnostic microbiology and infectious disease, Vol.65(1), pp.27-34

2009

DOI: 10.1016/j.diagmicrobio.2009.05.007

PMID: 19679232

View Online

Abstract

The accuracy of antifungal susceptibility testing is important for reliable resistance surveillance and for the clinical management of patients with serious infections due to Candida spp. Our primary objective was to compare the results of fluconazole and voriconazole disk diffusion testing of 3227 Candida spp. performed by 47 centers participating in the ARTEMIS program with disk diffusion and MIC results obtained by the central reference laboratory. The overall categoric agreement between participant disk diffusion test results and reference MIC results was 87% for fluconazole and 95.2% for voriconazole. Likewise good agreement was observed between participant disk diffusion test results and reference laboratory disk diffusion test results, with an agreement of 90.5%, 1% very major error (VME), and 3.4% major error (ME) for fluconazole and 94.2%, 1.1% VME, and 2.5% ME for voriconazole. The disk diffusion test was reliable for detecting those isolates of Candida spp. that were characterized as resistant to fluconazole and voriconazole by MIC testing. External quality assurance data obtained by surveillance programs such as the ARTEMIS Global Antifungal Surveillance Program ensure the generation of useful surveillance data and result in the continued improvement of antifungal susceptibility testing protocols.

Fluconazole

Surveillance

Candida

Voriconazole

Details

Title: Subtitle: Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program
Creators: Michael A Pfaller - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Linda Boyken - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Richard J Hollis - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Jennifer Kroeger - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Shawn A Messer - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Shailesh Tendolkar - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Daniel J Diekema - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Contributors: ARTEMIS DISK Global Antifungal Surveillance Group (Author)
Resource Type: Journal article
Publication Details: Diagnostic microbiology and infectious disease, Vol.65(1), pp.27-34
Publisher: Elsevier Inc
DOI: 10.1016/j.diagmicrobio.2009.05.007
PMID: 19679232
ISSN: 0732-8893
eISSN: 1879-0070
Language: English
Date published: 2009
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986366602771

Metrics

14 Record Views

26 Times Cited - Web of Science